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Abstract New type protein kinase C (PKC) 7] was found to be 
expressed in RAW 264.7 and J774A.1 macrophages, Madin-
Darby canine kidney (MDCK) cells and astrocytes by Western 
blot analysis. Both cytosol and membrane in macrophages and 
astrocytes express this isoform, however, the expression in the 
membrane is more abundant than that in the cytosol. On the 
other hand, only membrane PKCTJ was detected in MDCK cells. 
Exposure of the cells to 1 juM TPA for 10 min resulted in the 
translocation of PKCTJ from the cytosolic to the membrane 
fraction. This translocation maintained at a constant level after 
1.5, 3, 6 and 24 h TPA treatment. However, another new type 
PKC5 which expressed in the macrophages and astrocytes was 
down-regulated after long-term (6 and 24 h) TPA treatment. The 
immunoreactive band of PKCTJ in J774A.1 macrophages was 
blocked by the control PKCTJ antigenic peptide. Incubation of 
RAW 264.7 macrophages with UTP (1 ,10 and 100 /xM) resulted 
in the accumulation of inositol phosphates, indicating the 
presence of P 2 receptor-coupled PLC pathway in these cells. 
This natural activator UTP also induced translocation of PKCTJ 
from cytosol to the membrane in RAW 264.7 macrophages after 
1, 5 or 10 min treatment. Immunofluorescence microscopy 
revealed that in RAW 264.7 cells, PKCTJ is located in the 
cytoplasm organdie, plasma membrane and nuclear envelope. 
Stimulation of the cells with TPA resulted in translocation to the 
plasma membrane. This translocation of PKCTJ was still 
apparent after 24 h treatment with TPA. 
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1. Introduction 
Protein kinase C (PKC) comprises a family of isozymes that 
are pivotal in intracellular signal transduction [1,2]. It is acti-
vated by increased amount of diacylglycerol (DAG) in mem-
branes, which results from hydrolysis of inositol phospholip-
ids by phospholipase C (PLC) or from phosphatidylcholine 
(PC) by PC-PLC or by phospholipase D (PLD) [3]. This 
phospholipid-dependent serine/threonine kinase comprises at 
least 12 isoforms with different pat tern of tissue expression 
and is divided into conventional (a , Pi, Pn and y), new (5, e, 
Ti and 6) and atypical (£, X, t and u) isoforms [1]. Activation 
of P K C requires association with the membrane and is in-
duced by a number of activators and cofactors, these require-
ment differ for each isoform [4]. With the exception of the so 
called atypical P K C isoforms, the activity of membrane-asso-
ciated P K C is activated by the second messenger D A G . 
In addition to the natural activator D A G , P K C is activated 
with high specificity by the tumor promoting phorbol esters, 
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such as TPA [5]. For this reason, phorbol esters are often used 
in the study of the mechanism of P K C activation. From a 
response elicited by phorbol ester, it is common to infer 
P K C involvement in the regulation of cellular processes [5]. 
When cells are activated by physiological stimulants or by 
phorbol esters that act via P K C , the conventional and new 
but not atypical isoform X, in many different cell types become 
tightly associated with membrane fractions [6-9]. After long-
term treatment with phorbol esters, down-regulation of both 
conventional and new [8] but not atypical isoform C, was also 
observed [7,8,10,11]. Here we demonstrated that R A W 264.7 
and J774A.1 macrophages, Madin Darby canine kidney 
( M D C K ) cells and astrocytes expressed new P K C isoform T| 
and this isoform was translocated but not down-regulated 
after treatment of these cells with TPA. This result was further 
confirmed by immunofluorescence staining. U T P , which acts 
through P 2 receptor coupled PLC pathway in R A W 264.7 
macrophages to mediate phosphatidylinositol hydrolysis, 
also translocated P K C T ) from the cytosol to the membrane. 
2. Materials and methods 
2.1. Materials 
Affinity purified rabbit polyclonal antibody against peptide se-
quence unique to PKCn and control peptide were purchased from 
Santa Cruz Biotechnology (California). Rabbit affinity-purified anti-
body against PKC8-specific peptide sequence, Dulbecco's modified 
Eagle medium (DMEM), fetal calf serum (FCS), penicillin and strep-
tomycin were obtained from Gibco BRL (Gaithersberg, MD). Fluo-
rescein isothiocyanate (F1TC) conjugates of goat anti-rabbit IgG was 
from Cappel (Aurora, Ohio). TPA was from LC Services (Woburn, 
MA). UTP was from Sigma Chemical Co. (St. Louis, MO). Reagents 
for SDS-polyacrylamide gel electrophoresis (PAGE) were from Bio-
Rad. Myo-[3H]inositol (23.5 Ci/mmol) was from Dupont-New Eng-
land Nuclear. The horseradish peroxidase-labeled donkey anti-rabbit 
second antibody and the ECL detecting reagent were purchased from 
Amersham International. 
2.2. Cell cultures 
RAW 264.7 and J774A.1 macrophages and MDCK cells, purchased 
from ATCC (Rockville, MD), were grown in DMEM supplemented 
with 10% FCS, 100 U/ml penicillin and 100 u.g/ml streptomycin. Pri-
mary culture of astrocytes was prepared from cerebellum of 8-day old 
Wistar rats as described previously [12]. All the cells were plated in 
145 mm Petri dishes for PKCn and 8 assay and for nuclear protein 
separation; plated in 6-well plates for phosphatidylinositol hydrolysis 
assay and plated on 24-mm glass coverslip in 35 mm dishes for im-
munofluorescence staining. Cells were grown in an atmosphere of 5% 
C02/95% 0 2 humidified air at 37°C. 
2.3. Preparation of cell extracts and immunoblot analysis of PKCr\ and 
PKCS in macrophages, MDCK cells and astrocytes 
Cells in 145 mm petri dishes were treated with 1 u.M TPA in the 
growth medium for periods of 10 min, 1.5, 3, 6 or 24 h and RAW 
264.7 cells were treated with UTP for 1, 5 and 10 min before harvest-
ing. The cells were then rapidly washed with ice-cold phosphate buffer 
saline (PBS), scraped and collected by centrifugation at lOOOXg for 
10 min. The preparation of cell extracts and immunoblot analyses of 
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Fig. 1. Translocation and down-regulation of PKCn (A) and PKC8 (B) in macrophages, astrocytes and MDCK cells in response to TPA. Cells 
were treated with 0.1% DMSO (24 h) or 1 uM TPA for different times (10 min and 1.5, 3, 6 and 24 h) and then fractionated into cytosolic 
and membrane fractions, the proteins were separated by 10% SDS-PAGE, transferred to nitrocellulose paper, and immunodetected with PKCn-
and 8-specific antibodies. The autoradiography was obtained from ECL detection with three similar results. 
PKCn and 8 detected by ECL reagents were performed as described 
previously [8,12]. The peptide block of PKCn was performed by add-
ing antigenic PKCn peptide in the PKCr| antibody solution before 
incubation with the nitrocellulose membrane. 
2.4. Measurement of phosphatidylinositol hydrolysis in RAW264.7 
macrophages 
Phosphatidylinositol hydrolysis in RAW 264.7 macrophages was 
assessed by measuring the accumulation of [3H]inositol phosphates 
in cells labeled with myo-[3H]inositol (2.5 u,Ci/ml) for 24 h as previ-
ously described [12]. Cells were then washed three times with physio-
logical saline solution (PSS) to remove free myo-[3H]inositol. After 20 
min preincubation at 37°C in PSS containing 10 mM LiCl, UTP at 1, 
10 or 100 uM was added and incubation was performed for another 
15 min. 
2.5. Preparation of nuclear extracts 
RAW 264.7 cells grown in 145 cm dishes were treated with 1 U.M 
TPA in the growth medium for 10 min or 24 h before harvesting. The 
cells were then rapidly washed with ice-cold PBS, scraped. The col-
lected cells were resuspended in hypotonic buffer A (10 mM HEPES, 
pH 7.9, 10 mM KC1, 1.5 mM MgCl2, 0.5 mM PMSF, 1 ng/ml leu-
peptin, 1 mM NaF and 1 mM Na3V04) and incubated 15 min on ice. 
Cells were lysed by the addition of 0.5% NP-40 and mixed by inver-
sion, and the nuclei were pelleted. The nuclear pellet is resuspended in 
extraction buffer B (added 1 mM EDTA and replaced 10 mM KC1 
with 450 mM NaCl in buffer A) and incubated for 15 min at 4°C on 
rocking platform and then the nuclear extracts were centrifuged. 
2.6. Immunofluorescence staining 
Raw 264.7 cells grown in coverslips were treated with 1 U.M TPA in 
the growth medium for 10 min or 24 h. The cells were then rapidly 
washed with PBS and fixed at room temperature for 15 min with 3% 
paraformaldehyde. After washing with PBS, cells were blocked and 
permeabilized with 1% BSA in Tris-buffer saline containing 0.1% Tri-
ton X-100 for 20 min at room temperature. The cells were then in-
cubated with anti-PKCn antibody (1 : 50) for 30 min, washed exten-
sively, and then stained for 30 min with anti-rabbit IgG-fluorescein 
(1 : 2000). After additional washes, the coverslips were rinsed in dis-
tilled water and mounted on glass slides using mounting medium (2% 
n-propyl gallate in 60% glycerol and 0.1 M PBS, pH 8.0). Optical 
sections of the immunostained cells were visualized and photographed 
with an Zeiss Axiovert inverted microscope equipped with epifiuores-
cence. In negative controls, the primary antibody was omitted and no 
background staining was seen. 
3. Results 
3.1. Expression of PKCx\ and 5 in macrophages, astrocytes 
and MDCK cells after short-term and long-term TPA 
treatment 
Using PKCri-specific antibody, the abundant expression of 
this isoform in both cytosol and membrane of RAW264.7 and 
J774A.1 macrophages was found (Fig. 1A). It appeared in the 
immunoblot as a doublet with a major immunoreactive band 
Cytosol 
(A) 
(B) 
Membrane 
0 10' 1.5 3 6 24 0 10' 1.5 3 6 24h 
Fig. 2. Protein immunoblots showing translocation of PKCr| in J774A.1 macrophages after treatment with TPA. Transferred nitrocullose paper 
was blotted with PKCn antibody in the absence (A) or presence (B) of PKCn peptide antigen. Cells were treated with 1 (xM TPA for different 
times (10 min and 1.5, 3, 6 and 24 h) and separated into cytosolic and membrane fractions that were subjected to SDS-PAGE. Transferred ni-
trocellulose papers were blotted with PKCn antibody (A) and PKCn antibody plus PKCn peptide antigen (B), respectivley. The autoradiogra-
phy was obtained from ECL detection with three similar results. 
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Fig. 3. Stimulation of [3H]inositol phosphates formation induced by 
UTP in RAW 264.7 macrophages. Prelabeled cells were washed 
with physiological salt solution and lithium-dependent accumulation 
of [3H]inositol phosphates was measured in the presence of UTP at 
indicated concentrations at 37°C for 15 min. Results are expressed 
as the mean ± S.E.M. of three experiments. Basal [3H]inositol phos-
phates accumulation was 400 ±21 cpm/well. 
at 82 kDa and one minor band above 82 kDa. Inclusion of 
the control antigenic PKCr| peptide, which was used for rais-
ing this antibody, in the immunoblot analysis prevented com-
pletely the detection of these two immunoreactive bands of 
PKCn (Fig. 2). The expression of PKCn in astrocytes is in 
both cytosol and membrane as well, however, that in MDCK 
cells is only in the membrane (Fig. 1A). After treatment of 
cells with 1 uM TPA for 10 min, 1.5, 3, 6 and 24 h, trans-
location of PKCn was seen after 10 min treatment. This trans-
location was maintained even after long-term 24 h treatment 
(Fig. 1A). On the other hand, another new type PKC8, which 
also abundantly expressed in the macrophages and astrocytes, 
was translocated after 10 min TPA treatment and gradually 
down-regulated after 1.5, 3 and 6 h treatment. A complete 
down-regulation of PKC5 was seen after 24 h TPA treatment 
(Fig. IB). 
3.2. Effect of UTP on phosphatidylinositol hydrolysis and on 
PKCx[ translocation in RA W 264.7 macrophages 
UTP (1 uM) induced a 6-fold increase of inositol phos-
phates formation in RAW 264.7 macrophages. Both 10 uM 
and 100 uM UTP induced a maximal 10-fold increase of in-
ositol phosphates formation, indicating the presence of P2 
receptor coupled-PLC pathway to mediate phosphatidylinosi-
tol turnover in these cells (Fig. 3). A 1, 5 and 10 min exposure 
of RAW 264.7 macrophages to 100 uM UTP, the natural 
activator, also induced translocation of PKCr) from cytosol 
to the membrane (Fig. 4). 
3.3. PKCx[ is located in the cytosol, plasma membrane and 
nuclear envelope in RA W 264.7 cells 
Immunofluorescence staining showed the expression of 
PKCr| in certain cytoplasm organelle, plasma membrane 
and at the nuclear envelope in RAW 264.7 cells (Fig. 5A). 
Western blot of nuclear extracts did show the expression as 
well (Fig. 5E). Stimulation of cells with TPA leads to trans-
location of PKCn to the plasma membrane (Fig. 5C). This 
event is lasted after 24 h treatment with TPA (Fig. 5D), con-
firming the translocation but not down-regulation of PKCr| to 
plasma membrane in Western blot analysis (Fig. 1A) 
4. Discussion 
The new type PKCn has a unique tissue distribution [13,14]. 
Unlike other members of the PKC family, nPKCr| is ex-
pressed predominantly in epithelial tissues, including skin, 
tongue, esophagus, stomach, intestine, trachea and bronchus. 
In situ hybridization and immunohistochemical staining indi-
cated that nPKCr| is localized in differentiated or differentiat-
ing epithelial cells rather than proliferating basal cells [14]. 
Particularly in the skin, it is localized exclusively in the upper-
most granule layers [15], which consists of the terminally dif-
ferentiating keratinocytes with keratohyalin granules. In addi-
tion to epithelial cells, we found nPKCn also expressed in 
macrophages RAW 264.7 and J774A.1, astrocytes and 
MDCK cells in the present study. There is a doublet with 
molecular weight around 82 kDa in the immunoblot of mac-
rophages but not astrocytes and MDCK cells (Fig. 1A). Osa-
da et al. [13] reported a 82 kDa PKCn expressed in trans-
fected COS cells, while Livneh and coworkers [16,17] reported 
a 86 kDa PKCr| expressed in transfected COS cells and in 
several skin-derived cell lines. The doublet in the present mac-
rophages might be equivalent to 82 and 86 kDa PKCn, re-
spectively, since they were completely blocked by PKCn anti-
genic peptide (Fig. 2). Translocation of PKCr) from cytosol to 
the particulate fraction was seen in response to 10 min treat-
ment with TPA in macrophages, MDCK cells and astrocytes 
[18] (Fig. 1A) and in response to 1, 5 and 10 min treatment 
with UTP in RAW 264.7 macrophages (Fig. 4). The trans-
location of PKCn was still apparent after 24 h treatment with 
TPA in condition complete down-regulation of another new 
type PKC8 in macrophages and astrocytes [12] was seen (Fig. 
IB). Therefore, nPKCn was translocated but not down-regu-
lated by TPA in these three types of cells. Previous report [16] 
suggested that PKCr| is the nuclear receptor for phorbol esters 
in skin-derived cell lines. Greif et al. [17] using immunofluo-
rescence staining indicated the distribution of PKCr| through-
out the nucleus but not cytosol of human epidermal carcino-
ma A431 cells, skin keratinocyte cell line HaCaT and skin 
squamous carcinoma cell line SCL-1. PKCr| was involved in 
the transcriptional activation of the human transglutaminase 
1 gene which is expressed during the terminal differentiation 
of keratinized squamous epithelium to form cornified cell en-
velop in differentiated keratinocytes [19]. However, by chem-
ical and morphological analyses, Chida et al. [20] reported the 
localization of PKCn exclusively on the rough endoplasmic 
reticulum and outer nuclear membrane in keratocytes. Our 
results from RAW 264.7 cells are somewhat similar to this 
finding. Western blot showed the expression of PKCn in nu-
clear extracts (Fig. 5E) in addition to cytosol and membrane 
and immunofluorescence staining confirmed this result (Fig. 
5A). Short-term treatment (10 min) with TPA resulted in the 
translocation of this isoform to the plasma membrane, and 
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Fig. 4. Immunoblot detection of translocation of PKCn in RAW 
264.7 macrophages by UTP. Cells were treated with 100 uM UTP 
for 1, 5 and 10 min, the cytosolic and membrane fractions were pre-
pared as described in Section 2.3. Samples (100 |ig of protein) were 
separated by SDS-PAGE, transferred to nitrocellulase paper and im-
munoreacted with PKCn antibody (1 : 300 dilution). The autora-
diography was a representative of three similar results. 
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Fig. 5. P K C T | is located in the cytoplasm, plasma membrane and nuclear envelope. Immunofluorescent staining of RAW 264.7 macrophages 
with affinity-purified PKCn antibody (1 : 50). Cells were fixed and stained as described in Section 2. Control (A) and image of phase contrast 
(B), after TPA 10 min stimulation (C), after TPA 24 h treatment (D) and Western blot of PKCn in (N) nuclear extracts and (C) cytosol (E). 
this phenomenon is still apparent after 24 h TPA treatment 
(Fig. 1, Fig. 5C and 5D). PKCn in astrocytes and MDCK 
cells was not related to the regulation of ATP-induced phos-
phatidylinositol hydrolysis [18] and arachidonic acid release 
[21], respectively. The functional role of PKCT) in nonepithe-
lial cells, especially in macrophages, remains to be investi-
gated. 
The translocation of PKCT) and resistance to down-regula-
tion by TPA would suggest that in TPA-down-regulated cells, 
often described as PKC-depleted cells, the cellular pathways 
previously identified as PKC independent may still be regu-
lated by PKCn. Hence, interpretation of experiments involv-
ing phorbol ester treatment, at least in the cells which ex-
pressed PKCr|, should take into account the activation of 
this isoform. The nuclear PKCn is also resistant to down-
regulation by TPA in A431, HaCa T and SCL-1 cells [17]. 
In contrast, complete down-regulation of PKCT) in murine 
epidermis by 18 h TPA or bryostatin treatment was reported 
by Gschwendt et al. [11]. 
In summary, PKCT) expressing cells could be activated by 
TPA and natural activator, while this isoform is not down-
regulated by TPA. PKCn may be responsible for some of the 
actions induced by phorbol esters or natural activator in the 
cell membrane or nucleus, at least in macrophages. The exact 
molecular mechanisms involved remain to be elucidated. 
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